Frontlight ResearchEarly access
Chronic lymphocytic leukaemia trials in Italy
43 of 47 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Where
- Alessandria, Bologna, Brescia, Meldola (FC), Milan, Ravenna
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT07221500 - Phase 3Not yet taking people in ItalyROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Where
- Bergamo, Cuneo, Ferrara, Milan, Naples, Pisa, Ravenna, Rome, Rozzano, Terni
- Age
- 18 years and over
- People
- 306 worldwide
- Run by
- Newave Pharmaceutical Inc
See details and how to joinNCT07342478 · EU 2026-525656-28-00 - Phase 1/2Taking peopleSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Bologna, Brescia, Genova, Milan, Monza, Naples, Pavia, Rome, Torino
- Age
- 1 year to 17 years
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00 - Phase 3Taking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- Bari, Florence, Milan, Naples, Novara, Pavia, Perugia, Rome
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - Phase 3Taking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Alessandria, Milan, Reggio Emilia
- Age
- 18 years and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - Phase 1Taking peopleA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Brescia, Milan, Sant'Andrea Delle Fratte (PG)
- Age
- 18 years and over
- People
- 332 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05091424 - Phase 2Taking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Bari, Ferrara, Florence, Milan, Novara, Padova, Palermo, Perugia, Rome
- Age
- 18 years and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - Phase 4Taking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Alessandria, Florence, Messina, Monza, Perugia, Rome, Terni
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - Phase 4Taking peopleAcalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
- Where
- Cagliari, Florence, Milan, Pavia, Perugia
- Age
- 18 years and over
- People
- 33 worldwide
- Run by
- AstraZeneca AB
See details and how to join2023-510147-37-00 - Phase 1/2Not yet taking people in ItalyA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Bologna, Milan
- Age
- 18 years and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - Phase 2Taking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Bari, Bologna, Brescia, Milan, Naples, Pavia, Reggio Emilia, Roma
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - Phase 1/2Not yet taking people in ItalyA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Where
- Bologna, Rozzano, Verona
- Age
- 18 years and over
- People
- 258 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00 - Phase 3Taking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Bari, Cagliari, Catania, Ferrara, Milan, Modena, Pagani
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - Phase 2Taking peopleMAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
- Where
- Meldola, Milan, Padova, Ravenna
- Age
- 18 years to 130 years
- People
- 80 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07024706 · EU 2024-518858-17-00 - Phase 3Not yet taking people in ItalySingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Brescia, Candiolo, Catania, Florence, Milan, Rome, Varese
- Age
- 18 years and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Bologna, Milan, Roma, Verona
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 3Taking peopleA phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
- Where
- Bari, Cagliari, Catania, Milan, Padova, Palermo, Perugia, Rome, Varese
- Age
- 18 years and over
- People
- 746 worldwide
- Run by
- University Of Cologne
See details and how to join2023-510294-34-00 - Phase 4Not yet taking people in ItalyRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- Bologna, Busto Arsizio, Milan, Modena, Novara, Padova, Perugia, Pescara, Ravenna, Rimini, Rome
- Age
- 18 years and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 - Phase 3Not yet taking people in ItalyA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Where
- Meldola, Ravenna, Rome, Tricase
- Age
- 18 years and over
- People
- 49 worldwide
- Run by
- Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Bologna, Milan
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - Phase 3Taking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bologna, Milan, Padova
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - Phase 3Taking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Bologna, Florence, Milan, Padova, Rome
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - Phase 4Taking peopleAcalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
- Where
- Cagliari, Florence, Milan, Pavia, Perugia
- Age
- 18 years to 130 years
- People
- 60 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06651970 - Phase 2Taking peopleA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibitor (BCL-2i) (DAYBreak CLL-201)
- Where
- Alessandria, Bergamo, Bologna, Brescia, Meldola, Milan, Milano, Ravenna, Rome, Turin
- Age
- 18 years and over
- People
- 45 worldwide
- Run by
- Nurix Therapeutics Inc.
See details and how to join2025-521088-10-00 - Phase 3Taking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Alexandria, Bologna, Meldola, Milan, Reggio Emilia
- Age
- 18 years and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00